 |
Home | Site Map | Contact Us |
Trenton H. Buchanan, D.M.D.
Thomas E. Dudney, D.M.D.
140 Village Street
Suite 203
Birmingham, AL 35242
View Map
Call or E-mail Our Hoover Office Today
To schedule an appointment, just dial (205) 981-7775 or contact us using our convenient e-mail contact.
OraVerse
Your
comfort is an important priority in our practice. So if you're someone who dislikes the lingering numbness of local anesthesia
and the way it can limit your daily activities, an innovative solution is here. Our office is now offering a new product called
OraVerse™.
OraVerse is the first and only product of its kind to rapidly reverse the effects of local anesthetics containing a vasoconstrictor so you can feel, speak, smile, and drink normally in approximately half the time.1 OraVerse is not recommended for use in children less than 6 years of age or weighing less than 15 kg (33 lbs).
If you're one of the many patients averse to the lingering numbness from local anesthesia, let's discuss whether OraVerse is the right choice for you during your next dental visit.
For more information, please visit www.OraVerse.com.
Important Safety Information
Tachycardia, bradycardia, and cardiac arrhythmias may occur with the use of phentolamine or other alpha-adrenergic blocking agents. Although such effects are uncommon with OraVerse (phentolamine mesylate), clinicians should be alert to the signs and symptoms of these events, particularly in patients with a history of cardiovascular disease. Following parenteral use of phentolamine at doses between 5 to 15 times higher than the recommended dose of OraVerse, myocardial infarction, and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states.
1 Median time to recovery of normal sensation was reduced by 85 minutes (55%) in the mandible and by 83 minutes (62%) in the maxilla compared to control. Median time to recovery of normal function was reduced by 60 minutes (50%) in the mandible and by 45 minutes (43%) in the maxilla.